<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00751634</url>
  </required_header>
  <id_info>
    <org_study_id>1507-009</org_study_id>
    <nct_id>NCT00751634</nct_id>
  </id_info>
  <brief_title>Temperature Control in Central Fever in the Neuro-ICU</brief_title>
  <official_title>Temperature Control in Central Fever in the Neuro-ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gaymar Industries, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few treatments for central fever (fever that is due to the central nervous system,
      as opposed to an infectious source). We hypothesize that an externally applied cooling
      blanket will reduce temperature in neurologically ill patients with central fever.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care</measure>
    <time_frame>baseline, one, two and six hours after application.</time_frame>
    <description>Core temperature (in degrees Fahrenheit, F) throughout the study period. The cooling blanket was in place throughout the study period unless severe shivering led to termination per protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Cooling Device to Core Temperature &lt; 100.4F</measure>
    <time_frame>Six hours</time_frame>
    <description>For all patients, the time until the core temperature (measured with a urinary catheter in place for usual clinical care) was &lt;100.4F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Shivering</measure>
    <time_frame>six hours</time_frame>
    <description>Severe shivering as measured by the bedside shivering assessment scale: 0 None: no shivering noted on palpation of the masseter, neck, or chest wall
Mild: shivering localized to the neck and/or thorax only
Moderate: shivering involves gross movement of the upper extremities (in addition to neck and thorax)
Severe: shivering involves gross movements of the trunk and upper and lower extremities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hypotension</measure>
    <time_frame>six hours</time_frame>
    <description>New systolic blood pressure &lt; 100 mm Hg, or new vasopressor use during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Arrhythmia</measure>
    <time_frame>Six hours</time_frame>
    <description>New ventricular tachycardia, ventricular fibrillation, atrial fibrillation or other unstable cardiac rhythm</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Fever</condition>
  <condition>Brain Hemorrhage</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of the Gaymar Rapr-Round device per approved use</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gaymar Rapr-Round (external cooling blanket)</intervention_name>
    <description>Application of the device per its approved labeling</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two or more days with core temperature â‰¥ 100.4F

          -  Approval of the patient's primary attending physician

          -  Need for core temperature measurement independent of the study.

          -  Admission to the Neuro-ICU [intensive care unit] for an underlying condition

        Exclusion Criteria:

          -  Evidence for an infectious cause of fever, such as pneumonia, bacteremia, CNS [central
             nervous system] infection or urinary tract infection.

          -  Expected death from any cause

          -  Known sensitivity to the device

          -  History of pre-admission hypothalamic dysfunction or known temperature dysregulation

          -  Use of 2 or more vasopressor medications, since this may make a local skin reaction to
             the device more likely

          -  Hemodynamic instability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Naidech, MD MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2008</study_first_submitted>
  <study_first_submitted_qc>September 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2008</study_first_posted>
  <results_first_submitted>January 9, 2012</results_first_submitted>
  <results_first_submitted_qc>March 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2012</results_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Andrew Naidech</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>fever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care</title>
        <description>Core temperature (in degrees Fahrenheit, F) throughout the study period. The cooling blanket was in place throughout the study period unless severe shivering led to termination per protocol.</description>
        <time_frame>baseline, one, two and six hours after application.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group at 0, 1, 2, 6 Hours</title>
            <description>Application of the Gaymar Rapr-Round device per approved use</description>
          </group>
        </group_list>
        <measure>
          <title>Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care</title>
          <description>Core temperature (in degrees Fahrenheit, F) throughout the study period. The cooling blanket was in place throughout the study period unless severe shivering led to termination per protocol.</description>
          <units>degrees F</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.8" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Cooling Device to Core Temperature &lt; 100.4F</title>
        <description>For all patients, the time until the core temperature (measured with a urinary catheter in place for usual clinical care) was &lt;100.4F</description>
        <time_frame>Six hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Cooling Device to Core Temperature &lt; 100.4F</title>
          <description>For all patients, the time until the core temperature (measured with a urinary catheter in place for usual clinical care) was &lt;100.4F</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Shivering</title>
        <description>Severe shivering as measured by the bedside shivering assessment scale: 0 None: no shivering noted on palpation of the masseter, neck, or chest wall
Mild: shivering localized to the neck and/or thorax only
Moderate: shivering involves gross movement of the upper extremities (in addition to neck and thorax)
Severe: shivering involves gross movements of the trunk and upper and lower extremities</description>
        <time_frame>six hours</time_frame>
        <population>All participants were analyzed for the outcome of BSAS=3</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Shivering</title>
          <description>Severe shivering as measured by the bedside shivering assessment scale: 0 None: no shivering noted on palpation of the masseter, neck, or chest wall
Mild: shivering localized to the neck and/or thorax only
Moderate: shivering involves gross movement of the upper extremities (in addition to neck and thorax)
Severe: shivering involves gross movements of the trunk and upper and lower extremities</description>
          <population>All participants were analyzed for the outcome of BSAS=3</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hypotension</title>
        <description>New systolic blood pressure &lt; 100 mm Hg, or new vasopressor use during study period</description>
        <time_frame>six hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypotension</title>
          <description>New systolic blood pressure &lt; 100 mm Hg, or new vasopressor use during study period</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Arrhythmia</title>
        <description>New ventricular tachycardia, ventricular fibrillation, atrial fibrillation or other unstable cardiac rhythm</description>
        <time_frame>Six hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Arrhythmia</title>
          <description>New ventricular tachycardia, ventricular fibrillation, atrial fibrillation or other unstable cardiac rhythm</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Application of the Gaymar Rapr-Round device per FDA-approved use (temperature reduction in patients with fever in a monitored setting)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew Naidech</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-3335</phone>
      <email>a-naidech@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

